The administration of @entity2263 -agonists for paediatric XXXX and its adverse reaction in Australian and New Zealand emergency departments: a cross-sectional survey.

@entity1 @entity137 @entity3045 @entity565 @entity400 @entity2263 @entity4710
AIM: To determine the current use of @entity2263 -agonists, in particular @entity3045 , for the management of acute @entity565 in @entity1 in emergency departments throughout Australia and New Zealand. METHODS: A cross-sectional survey using a questionnaire that sought to determine the current use of @entity3045 and any @entity137 in paediatric emergency departments. RESULTS: Out of 37 hospitals eligible as paediatric emergency departments, 33 (89.1%) responded to the survey, 54.5% having guidelines for the management of acute @entity565 . Of the paediatric emergency departments surveyed, 45.5% used metered-dose inhaler spacer combination in the treatment of mild to moderate @entity565 . All paediatric emergency departments used nebulized @entity3045 for acute severe @entity565 . In addition, 85% of paediatric emergency departments used continuous-infusion intravenous @entity3045 in unresponsive @entity1 , 63.6% administering a single-dose intravenous @entity3045 bolus before commencing the infusion. District paediatric emergency departments were more likely to treat with continuous-infusion intravenous @entity3045 outside of the intensive care unit. Clinical unresponsiveness to inhaled @entity3045 and clinical improvement were the reported criteria in all paediatric emergency departments for the use and cessation of intravenous @entity3045 . @entity137 were common: @entity400 (90%), hypokalaemia (45.5%) and @entity4710 (21%), particularly if continuous-infusion intravenous @entity3045 administered. Eight deaths from @entity565 were reported, none being related to @entity137 . CONCLUSION: We report a wide variation of @entity3045 use in paediatric emergency departments and a high prevalence of type A @entity137 when continuous-infusion intravenous @entity3045 therapy was administered. More evidence is needed on the clinical significance of the adverse effects reported in this study and optimal doses for the safe use of continuous-infusion intravenous @entity3045 therapy in paediatric emergency departments.
